ETAR antagonist ZD4054 exhibits additive effects with aromatase inhibitors and fulvestrant in breast cancer therapy, and improves in vivo efficacy of anastrozole

Author： Smollich Martin   Götte Martin   Fischgräbe Jeanett   Macedo Luciana   Brodie Angela   Chen Shiuan   Radke Isabel   Kiesel Ludwig   Wülfing Pia  

Publisher： Springer Publishing Company

ISSN： 0167-6806

Source： Breast Cancer Research and Treatment, Vol.123, Iss.2, 2010-09, pp. : 345-357

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Regulation of aromatase expression in breast cancer treated with anastrozole neoadjuvant therapy

By              

Experimental and Therapeutic Medicine, Vol. 5, Iss. 3, 2013-01 ,pp. : 902-906

Spandidos Publications

Access to resources Recommend Favorite

Aromatase Inhibitors: Indications for Breast Cancer Therapy

By Assikis V.J.  

American Journal of Cancer, Vol. 1, Iss. 2, 2002-02 ,pp. : 93-100

Adis International

Access to resources Recommend Favorite

The use of aromatase inhibitors in adjuvant therapy for early breast cancer

By Jonat Walter   Hilpert Felix   Maass Nicolai  

Cancer Chemotherapy and Pharmacology, Vol. 56, Iss. 1, 2005-11 ,pp. : 32-38

Springer Publishing Company

Access to resources Recommend Favorite

Endocrine Therapy for Advanced Breast Cancer: Beyond Tamoxifen and Aromatase Inhibitors

By  

Current Cancer Therapy Reviews, Vol. 6, Iss. 1, 2010-02 ,pp. : 51-61

Bentham Science Publishers

Access to resources Recommend Favorite

Aromatase Inhibitors for Treatment of Breast Cancer

By  

Current Cancer Therapy Reviews, Vol. 3, Iss. 1, 2007-02 ,pp. : 67-79

Bentham Science Publishers

Access to resources Recommend Favorite